Healthcare
Live Price
Offline$97.09
+0.00% today
Window Change
-61.16%
Window
Jun 23, 2025 → Apr 29, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 197 bars · Jun 23, 2025 → Apr 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
BerGenBio ASA (BRRGF) is a Healthcare stock with a market cap of $9.49B. The stock last traded around $97.09 and down 61.2% across the available one-year price window (Jun 23, 2025 → Apr 29, 2026). Baseline metrics include revenue growth of +139.5%, EPS growth of +41.6%, a dividend yield of 0.0%. What stands out right now is revenue +139.5%, EPS +41.6%, free cash flow +31.9% with operating margin -2133.2% and ROIC -172.1%. Valuation already assumes a fairly strong business story at price/sales 39.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines BRRGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
BRRGF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
BRRGF Max Drawdown
-99.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BRRGF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$601.0K
-22.4% YoY
FY Net Income
-$257.1M
+16.9% YoY
Free Cash Flow
-$234.4M
+22.7% YoY
Revenue Growth
+139.5%
EPS Growth
+41.6%
Gross Margin
98.1%
Net Margin
-1990.4%
Income statement
NOK
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 848K | 354K | 389K | 774K | 601K |
| Gross Profit | 848K | 354K | 389K | 774K | -89M |
| Operating Income | -151M | -192M | -306M | -314M | -261M |
| EBITDA | -134M | -190M | -301M | -308M | -256M |
| Net Income | -139M | -190M | -299M | -309M | -257M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
NOK
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 140M | 156M | 150M | 436M | 721M |
| Total Assets | 156M | 174M | 167M | 450M | 738M |
| Total Liabilities | 33M | 47M | 78M | 66M | 68M |
| Shareholder Equity | 123M | 127M | 88M | 384M | 670M |
| Total Debt | 818K | 418K | 275K | 2M | 2M |
| Net Debt | -139M | -156M | -150M | -434M | -719M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
234M
+22.8% YoY
Capital Expenditures
67K
Free Cash Flow
234M
+22.7% YoY
Key ratios
Gross Margin
98.1%
Operating Margin
-2133.2%
Net Margin
-1990.4%
ROE
-113.4%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.